Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Terrosa

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

- PMLiVE

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway

Eli Lilly HQ

Lilly gets early US approval for Ibrance rival abemaciclib

The breast cancer treatment, marketed as Verzenio, will also compete with Novartis' Kisqali

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

Biosimilars: what the future looks like

Biosimilars: what the future looks like

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

Eli Lilly HQ

Lilly’s abemaciclib data leaves potential uncertain

MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links